Raymond James analyst Dane Leone maintained a Hold rating on Voyager Therapeutics (VYGR) yesterday. The company’s shares closed last Thursday at $6.23, close to its 52-week low of $6.16.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 17.6% and a 65.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Allogene Therapeutics, and Ayala Pharmaceuticals.
Voyager Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.64, a 31.3% upside from current levels. In a report released today, Robert W. Baird also downgraded the stock to Hold with a $6.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.62 and a one-year low of $6.16. Currently, Voyager Therapeutics has an average volume of 481.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.